Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Cancer chemotherapy and pharmacology

Results: 1-25/178

Authors: KIM DK KIM HT TAI JH CHO YB KIM TS KIM KH PARK JG HONG WS
Citation: Dk. Kim et al., PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF A NEW PLATINUM COMPOUND, CIS-MALONATO[(4R,5R) 4,5-BIS(AMINOMETHYL)-2-ISOPROPYL-1, 3-DIOXOLANE]PRATINUM(II), AS DETERMINED BY EX-VIVO PHARMACODYNAMICS, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 1-6

Authors: TOKO T SHIBATA J SUGIMOTO Y YAMAYA H YOSHIDA M OGAWA K MATSUSHIMA E
Citation: T. Toko et al., COMPARATIVE PHARMACODYNAMIC ANALYSIS OF TAT-59 AND TAMOXIFEN IN RATS BEARING DMBA-INDUCED MAMMARY-CARCINOMA, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 7-13

Authors: SOMMADOSSI JP CRETTON EM KIDD LB MCCLURE HM ANDERSON DC ELKOUNI MH
Citation: Jp. Sommadossi et al., EFFECTS OF 5-BENZYLACYCLOURIDINE, AN INHIBITOR OF URIDINE PHOSPHORYLASE, ON THE PHARMACOKINETICS OF URIDINE IN RHESUS-MONKEYS - IMPLICATIONS FOR CHEMOTHERAPY, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 14-22

Authors: JOHNSSON A OLSSON C NYGREN O NILSSON M SEIVING B CAVALLINSTAHL E
Citation: A. Johnsson et al., PHARMACOKINETICS AND TISSUE DISTRIBUTION OF CISPLATIN IN NUDE-MICE - PLATINUM LEVELS AND CISPLATIN DNA-ADDUCTS, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 23-31

Authors: ISRAEL VK JIANG C MUGGIA FM TULPULE A JEFFERS S LEICHMAN L MORROW CP ROMAN L LEICHMAN CG CHAN KK
Citation: Vk. Israel et al., INTRAPERITONEAL 5-FLUORO-2'-DEOXYURIDINE (FUDR) AND (S)-LEUCOVORIN FOR DISEASE PREDOMINANTLY CONFINED TO THE PERITONEAL-CAVITY - A PHARMACOKINETIC AND TOXICITY STUDY, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 32-38

Authors: GOSLAND MP GOODIN S YOKEL RA SMITH M JOHN WJ
Citation: Mp. Gosland et al., A PHASE-I TRIAL OF 5-DAY CONTINUOUS-INFUSION CISPLATIN AND INTERFERON-ALPHA, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 39-46

Authors: LAUNAYILIADIS MC BRUNO R COSSON V VERGNIOL JC OULIDAISSA D MARTY M CLAVEL M AAPRO M LEBAIL N ILIADIS A
Citation: Mc. Launayiliadis et al., POPULATION PHARMACOKINETICS OF DOCETAXEL DURING PHASE-I STUDIES USINGNONLINEAR MIXED EFFECT MODELING AND NONPARAMETRIC MAXIMUM-LIKELIHOOD-ESTIMATION, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 47-54

Authors: HUSKEN BCP DEJONG J BEEKMAN B ONDERWATER RCA VANDERVIJGH WJF BAST A
Citation: Bcp. Husken et al., MODULATION OF THE IN-VITRO CARDIOTOXICITY OF DOXORUBICIN BY FLAVONOIDS, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 55-62

Authors: ANDO N NAKAJIMA T MASUDA H KAWABATA Y IWAI M WATANABE M KAGITANI Y YAMADA N TSUKAGOSHI S
Citation: N. Ando et al., ANTIMICROTUBULE EFFECTS OF THE NOVEL ANTITUMOR BENZOYLPHENYLUREA DERIVATIVE HO-221, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 63-69

Authors: BRUSERUD O NESTHUS I PAWELEC G
Citation: O. Bruserud et al., IN-VITRO EFFECT OF R-VERAPAMIL ON ACUTE MYELOGENOUS LEUKEMIA BLAST CELLS - STUDIES OF CYTOKINE SECRETION AND CYTOKINE DEPENDENT BLAST PROLIFERATION, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 70-78

Authors: OLVER IN WEBSTER LK MILLWARD MJ STOKES KH BISHOP JF
Citation: In. Olver et al., A PHASE-I AND PHARMACOKINETICS STUDY OF PROLONGED AMBULATORY-INFUSIONCARBOPLATIN, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 79-85

Authors: MOORE MJ KAIZER L ERLICHMAN C MYERS R FELD R THIESSEN JJ FINE S
Citation: Mj. Moore et al., A CLINICAL AND PHARMACOLOGICAL STUDY OF 5-FLUOROURACIL, LEUCOVORIN AND INTERFERON-ALFA IN ADVANCED COLORECTAL-CANCER, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 86-90

Authors: MADER RM ZILG H SCHLAPPACK O STEGER GG BAUR M GREIFENBERG B HEBERLE U DITTRICH C
Citation: Rm. Mader et al., PHARMACOKINETICS OF 4'O-TETRAHYDROPYRANYLADRIAMYCIN GIVEN ON A WEEKLYSCHEDULE IN PATIENTS WITH ADVANCED BREAST-CANCER, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 91-96

Authors: GAMELIN E ALLAIN P MAILLART P TURCANT A DELVA R LORTHOLARY A LARRA F
Citation: E. Gamelin et al., LONG-TERM PHARMACOKINETIC BEHAVIOR OF PLATINUM AFTER CISPLATIN ADMINISTRATION, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 97-102

Authors: CUMMINGS J MEIKLE I MACPHERSON JS SMYTH JF
Citation: J. Cummings et al., ACCUMULATION OF ANTHRACENYL AMINO-ACID TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITORS IN DRUG-SENSITIVE AND DRUG-RESISTANT HUMAN OVARIAN-CANCER CELL-LINES DETERMINED BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 103-109

Authors: BARBERIHEYOB M WEBER B MERLIN JL DITTRICH C DEBRUIJN EA LUPORSI E GUILLEMIN F
Citation: M. Barberiheyob et al., EVALUATION OF PLASMA 5-FLUOROURACIL NUCLEOSIDE LEVELS IN PATIENTS WITH METASTATIC BREAST-CANCER - RELATIONSHIPS WITH TOXICITIES, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 110-116

Authors: JOEL SP CLARK PI SLEVIN ML
Citation: Sp. Joel et al., STABILITY OF THE IV AND ORAL FORMULATIONS OF ETOPOSIDE IN SOLUTION, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 117-124

Authors: JOEL SP CLARK PI HEAP L WEBSTER L ROBBINS S CRAFT H SLEVIN ML
Citation: Sp. Joel et al., PHARMACOLOGICAL ATTEMPTS TO IMPROVE THE BIOAVAILABILITY OF ORAL ETOPOSIDE, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 125-133

Authors: CARMICHAEL J PHILIP PA FORFAR C HARRIS AL
Citation: J. Carmichael et al., AN OPEN STUDY TO ASSESS THE SAFETY, TOLERANCE AND PHARMACOKINETICS OFAN INTRAVENOUS-INFUSION OF GRANISETRON GIVEN AT 3 MG OVER 30 S IN PATIENTS RECEIVING CHEMOTHERAPY FOR MALIGNANT DISEASE, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 134-138

Authors: CONLEY BA OHARA S WU SL MELINK TJ PARNES H PARDOE E EGORIN MJ VANECHO DA
Citation: Ba. Conley et al., PHASE-I TRIAL OF CHLOROGUINOXALINE SULFONAMIDE, WITH CORRELATION OF ITS PHARMACOKINETICS AND PHARMACODYNAMICS, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 139-149

Authors: LOS G BLOMMAERT FA BARTON R HEATH DD DENENGELSE L HANCHETT C VICARIO D WEISMAN R ROBBINS KT HOWELL SB
Citation: G. Los et al., SELECTIVE INTRAARTERIAL INFUSION OF HIGH-DOSE CISPLATIN IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER RESULTS IN HIGH TUMOR PLATINUM CONCENTRATIONS AND CISPLATIN-DNA ADDUCT FORMATION, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 150-154

Authors: PRZEPIORKA D MADDEN T IPPOLITI C ESTROV Z DIMOPOULOS M
Citation: D. Przepiorka et al., DOSING OF THIOTEPA FOR MYELOABLATIVE THERAPY, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 155-160

Authors: MILLWARD MJ NEWELL DR YUEN K MATTHEWS JP BALMANNO K CHARLTON CJ GUMBRELL L LIND MJ CHAPMAN F PROCTOR M SIMMONDS D CANTWELL BMJ CALVERT AH
Citation: Mj. Millward et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF PROLONGED ORAL ETOPOSIDE IN WOMEN WITH METASTATIC BREAST-CANCER, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 161-167

Authors: CHO J LEE Y LUTZKY J REDPATH L SLATER L
Citation: J. Cho et al., COLLATERAL SENSITIVITY TO RADIATION AND CISPLATINUM IN A MULTIDRUG-RESISTANT HUMAN LEUKEMIA-CELL LINE, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 168-172

Authors: LESSER GJ GROSSMAN SA ELLER S ROWINSKY EK
Citation: Gj. Lesser et al., THE DISTRIBUTION OF SYSTEMICALLY ADMINISTERED [H-3] PACLITAXEL IN RATS - A QUANTITATIVE AUTORADIOGRAPHIC STUDY, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 173-178
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>